Max Schreuer

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

Jeroen de Filette, Yanina Jansen, Max Schreuer et al. · The Journal of Clinical Endocrinology & Metabolism · 2016 · 249 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Max Schreuer, Yanina Jansen, Simon Planken et al. · The Lancet Oncology · 2017 · 184 citations

Medicine, Oncology, Pharmacology +16

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen et al. · Journal of Translational Medicine · 2016 · 138 citations · Full text

Medicine, Molecular Biology, Oncology +17

Characterization of the<i>in vivo</i>immune network of IDO, tryptophan metabolism, PD-L1, and<i>CTLA-4</i>in circulating immune cells in melanoma

Inès Chevolet, Reinhart Speeckaert, Max Schreuer et al. · OncoImmunology · 2015 · 109 citations · Full text

Medicine, Immunology, Oncology +17

Peritumoral indoleamine 2,3‐dioxygenase expression in melanoma: an early marker of resistance to immune control?

Inès Chevolet, Reinhart Speeckaert, Marc Haspeslagh et al. · British Journal of Dermatology · 2014 · 67 citations

Medicine, Immunology, Oncology +17